West Pharmaceutical Services (NYSE:WST) Updates Q3 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 2.140-2.240 for the period, compared to the consensus estimate of 2.130. The company issued revenue guidance of $820.0 million-$835.0 million, compared to the consensus revenue estimate of $815.1 million. West Pharmaceutical Services also updated its FY 2026 guidance to 8.850-9.050 EPS.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wolfe Research began coverage on West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective for the company. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. BNP Paribas Exane started coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 price objective on the stock. KeyCorp upped their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Finally, Morgan Stanley boosted their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services currently has an average rating of “Buy” and an average price target of $363.17.

West Pharmaceutical Services Stock Performance

NYSE:WST opened at $328.61 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.82. The firm’s 50-day moving average is $337.02 and its 200-day moving average is $287.43. West Pharmaceutical Services has a 52-week low of $223.83 and a 52-week high of $386.00. The company has a market cap of $23.22 billion, a price-to-earnings ratio of 42.08, a PEG ratio of 2.77 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same period in the previous year, the company posted $1.84 earnings per share. The company’s quarterly revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities research analysts anticipate that West Pharmaceutical Services will post 8.95 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 11.27%.

Insider Transactions at West Pharmaceutical Services

In other news, CAO Chad Winters sold 896 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares in the company, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by insiders.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West posted a strong second quarter, with adjusted EPS of $2.37 and revenue of $872.3 million, both above expectations. The company also raised full-year 2026 EPS guidance and gave third-quarter guidance that topped consensus, which supports the longer-term outlook. West Reports Second-Quarter 2026 Results
• Positive Sentiment: Demand remains strong for high-value injectable drug components, including products tied to GLP-1 and biologics markets, which helped drive the beat and the higher outlook. Reuters article on raised forecast
• Neutral Sentiment: Investors may be taking profits after the stock’s sharp earnings-driven surge in the prior session, especially since there was no major new negative company announcement or filing behind today’s weakness. Quiver Quantitative article
• Neutral Sentiment: Recent insider sales from two executives may add a small overhang, but the activity is limited and does not appear to be the main driver of the stock’s move. Insider trading details

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of West Pharmaceutical Services by 67.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock valued at $323,280,000 after buying an additional 473,547 shares during the period. Invesco Ltd. lifted its holdings in shares of West Pharmaceutical Services by 3.1% during the 4th quarter. Invesco Ltd. now owns 908,625 shares of the medical instruments supplier’s stock valued at $249,999,000 after purchasing an additional 27,340 shares in the last quarter. Corient Private Wealth LLC increased its stake in West Pharmaceutical Services by 354.9% during the 4th quarter. Corient Private Wealth LLC now owns 128,841 shares of the medical instruments supplier’s stock worth $35,449,000 after purchasing an additional 100,515 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in West Pharmaceutical Services by 6.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 8,629 shares of the medical instruments supplier’s stock valued at $2,374,000 after buying an additional 509 shares in the last quarter. Finally, State of Tennessee Department of Treasury boosted its holdings in shares of West Pharmaceutical Services by 94.2% in the fourth quarter. State of Tennessee Department of Treasury now owns 31,169 shares of the medical instruments supplier’s stock valued at $8,576,000 after buying an additional 15,115 shares during the period. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.